
ViewRay VRAY
Quarterly report 2023-Q1
added 05-11-2023
ViewRay Book Value 2011-2026 | VRAY
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value ViewRay
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.2 M | 170 M | 130 M | 216 M | 167 M | 1.99 M | -43.7 M | -6.96 M | 3.17 K | 3.03 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 216 M | -43.7 M | 71.7 M |
Quarterly Book Value ViewRay
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.3 M | 82.2 M | - | - | 148 M | 170 M | 118 M | 139 M | 164 M | 130 M | 130 M | 130 M | 130 M | 216 M | 216 M | 216 M | 216 M | 167 M | 167 M | 167 M | 167 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | -43.7 M | -43.7 M | -43.7 M | -43.7 M | -6.96 M | -6.96 M | -6.96 M | -6.96 M | -5.51 M | -5.51 M | 3.17 K | 3.17 K | 3.03 K | 3.03 K | 3.03 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 216 M | -43.7 M | 71.7 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
791 M | - | - | $ 1.05 B | ||
|
EDAP TMS S.A.
EDAP
|
50.1 M | $ 3.6 | 4.2 % | $ 135 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 2.22 | 2.78 % | $ 1.35 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 11.47 | 3.33 % | $ 325 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 17.12 | 0.47 % | $ 402 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.57 | -5.8 % | $ 35.5 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 66.26 | 15.05 % | $ 3.61 B | ||
|
Delcath Systems
DCTH
|
111 M | $ 11.26 | -2.34 % | $ 403 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.04 | -0.95 % | $ 17.6 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
43.2 M | - | 0.5 % | $ 219 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.85 | -2.78 % | $ 35.6 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.55 | -5.6 % | $ 963 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
450 M | $ 12.19 | -2.01 % | $ 483 M | ||
|
Insulet Corporation
PODD
|
1.52 B | - | - | $ 10.6 B | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 89.22 | -0.9 % | $ 12.1 B | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 2.4 | -0.83 % | $ 6.66 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 37.32 | 1.86 % | $ 1.16 B | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 45.7 | -5.42 % | $ 1.34 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 86.29 | 0.51 % | $ 3 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
22.4 B | $ 292.33 | -0.99 % | $ 112 B | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 83.2 | 0.35 % | $ 48.7 B | ||
|
TransMedics Group
TMDX
|
473 M | - | - | $ 2.48 B | ||
|
Tactile Systems Technology
TCMD
|
219 M | $ 25.3 | 5.2 % | $ 579 M | ||
|
Tandem Diabetes Care
TNDM
|
155 M | - | - | $ 1.23 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.39 | -1.73 % | $ 64.5 M |